Exploring diagnostic m6A regulators in primary open-angle glaucoma: insight from gene signature and possible mechanisms by which key genes function

BMC Medical Genomics, Journal Year: 2025, Volume and Issue: 18(1)

Published: March 24, 2025

The purpose of this study was to interrogate the potential role N6-methyladenosine (m6A) regulators in process trabecular meshwork (TM) tissue damage patients with primary open-angle glaucoma (POAG). Firstly, expression profile m6A TM tissues POAG comprehensively analyzed by bioinformatics analysis; Plasmid transfection and siRNA gene interference were used enhance or weaken levels YTHDC2 human cells (HTMCs); Cell migration ability detected transwell chamber assay; Immunofluorescence staining assay evaluate extracellular matrix (ECM) related proteins. Through analysis GSE27276 database, 5 different screened out. results random forest model showed that these exhibited diagnostic characteristic genes POAG. All samples could be effectively divided into two groups based on hub regulators. Immune cell infiltration indicated activated CD8+ T regulatory subtypes. HTMC oxidative stress TGF-β2 stimulation further constructed verify aforementioned regulators, it found mRNA same trend both models. silencing enhanced HTMCs increased synthesis ECM. However, when YTHDC2ΔYTH, which lacks YTH domain, is overexpressed HTMCs, there no significant change ECM ability. differentially expressed may serve as biomarkers for And, level changed under intervention, then exerted its regulation capability through modification, an important part disease

Language: Английский

Potential therapeutic targets for ischemic stroke in pre-clinical studies: Epigenetic-modifying enzymes DNMT/TET and HAT/HDAC

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: April 28, 2025

Ischemic stroke (IS) remains a leading cause of mortality and disability worldwide, driven by genetic predispositions environmental interactions, with epigenetics playing pivotal role in mediating these processes. Specific modifying enzymes that regulate epigenetic changes have emerged as promising targets for IS treatment. DNA methyltransferases (DNMTs), ten-eleven translocation (TET) dioxygenases, histone acetyltransferases (HATs), deacetylases (HDACs) are central to regulation. These maintain dynamic balance between methylation/demethylation acetylation/deacetylation, which critically influences gene expression neuronal survival IS. This review is based on both vivo vitro experimental studies, exploring the roles DNMT/TET HAT/HDAC IS, evaluating their potential therapeutic targets, discussing use natural compounds modulators develop novel treatment strategies.

Language: Английский